Phytochemicals for the treatment of inflammatory bowel diseases

被引:0
|
作者
Mathias Jochen Schneider
Heba Abdel-Aziz
Thomas Efferth
机构
[1] Johannes Gutenberg University,Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry
[2] Steigerwald Arzneimittelwerk GmbH,Scientific Department
来源
Phytochemistry Reviews | 2014年 / 13卷
关键词
Colitis; Inflammation; Medicinal chemistry; Crohn's disease; Pharmacognosy; Phytochemicals;
D O I
暂无
中图分类号
学科分类号
摘要
Inflammatory bowel diseases are a widespread problem of unclear aetiology in western as well as eastern societies. Even though there are established therapies to treat inflammatory bowel diseases, the clinical efficacy of these treatments is still not satisfactory. Plant derived compounds demonstrated promising results in pharmacological models of inflammation and few were also evaluated in early clinical trials. Classes of secondary metabolites with anti-inflammatory properties include isoprenoids, stilbenes, flavonoids, and alkaloids as well as structurally related compounds. Most of them affect nuclear factor kappa B activity, modulate enzymes and transcription factors, or reduce cytokine secretion. In addition to evaluating the anti-inflammatory abilities of natural products measured in vivo or in vitro models by immunological and enzymatic assays, some structure–activity-relationship studies were performed in order to find correlations between chemical features and anti-inflammatory activity for further optimization of chemical structures.
引用
收藏
页码:629 / 642
页数:13
相关论文
共 50 条
  • [41] 5-ASA treatment for inflammatory bowel diseases
    Behrens, R
    INFLAMMATORY BOWEL DISEASES AND CHRONIC RECURRENT ABDOMINAL PAIN, 1997, 91 : 135 - 136
  • [42] What is confirmed in the treatment of chronic inflammatory bowel diseases
    Manthey, Carolin F.
    Reher, Dominik
    Huber, Samuel
    INTERNIST, 2021, 62 (12): : 1269 - 1279
  • [43] Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases
    Saruta, Masayuki
    Papadakis, Konstantinos A.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (03) : 581 - +
  • [44] Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment
    Fragoulis, George E.
    Liava, Christina
    Daoussis, Dimitrios
    Akriviadis, Euangelos
    Garyfallos, Alexandros
    Dimitroulas, Theodoros
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (18) : 2162 - 2176
  • [45] Biosimilar biological drugs in the treatment of inflammatory bowel diseases
    Kaniewska, Magdalena
    Eder, Piotr
    Gasiorowska, Anita
    Gonciarz, Maciej
    Kierkus, Jaroslaw
    Malecka-Panas, Ewa
    Rydzewska, Grazyna
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2019, 14 (04): : 223 - 227
  • [46] Current status of biosimilars in the treatment of inflammatory bowel diseases
    Park, Dong Il
    INTESTINAL RESEARCH, 2016, 14 (01) : 15 - 20
  • [47] Probiotics for inflammatory bowel diseases: a promising adjuvant treatment
    Coqueiro, Audrey Y.
    Raizel, Raquel
    Bonvini, Andrea
    Tirapegui, Julio
    Rogero, Marcelo M.
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2019, 70 (01) : 20 - 29
  • [48] Surgical treatment of malignancies in chronic inflammatory bowel diseases
    Schardey, Josefine
    Zimmermann, Petra
    Burian, Maria
    Werner, Jens
    Kuehn, Florian
    COLOPROCTOLOGY, 2023, 45 (05) : 299 - 305
  • [49] Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases
    Williet, Nicolas
    Paul, Stephane
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (04) : 990 - 995
  • [50] Classical and recent advances in the treatment of inflammatory bowel diseases
    Sales-Campos, H.
    Basso, P. J.
    Alves, V. B. F.
    Fonseca, M. T. C.
    Bonfa, G.
    Nardini, V.
    Cardoso, C. R. B.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2015, 48 (02) : 96 - 107